laboratory specialized in the treatment of rare neurological diseases

« A disruptive technology, which can be applied in the treatment of numerous conditions »

THERANEXUS and Beyond Batten Disease Foundation (BBDF) announce the signing of a worldwide exclusive license for Batten disease drug candidate BBDF-101

Download PDF File (363 Ko)

THERANEXUS reports cash position as of September 30th 2019

Download PDF File (285 Ko)

THERANEXUS announces its first half 2019 results

Download PDF File (285 Ko)

A new milestone reached for Theranexus: inclusion of last patient in phase II trial for THN102 in Parkinson’s patients

Download PDF File (285 Ko)

THERANEXUS announces inclusion of last subject in its phase 1b trial of THN201

Download PDF File (397 Ko)

THERANEXUS announces the publication of two scientific papers and a presentation at the European pain congress (EFIC) to be held on 3-7 September in Valencia, Spain

Download PDF File (393 Ko)

THERANEXUS raises approximately 2.2 million euros in a placement reserved to a category of persons 

Dowload PDF File (615 Ko)

THERANEXUS announces the launch of a capital increase by private placement for a maximum amount of euro 4 million

Download PDF File (284 Ko)

THERANEXUS reports cash position as of June 30th 2019

Download PDF File (268 Ko)

Theranexus and Beyond Batten Disease Foundation (BBDF) announce agreement in
principle to develop and market Batten disease drug candidate BBDF 101

Download PDF File (416 Ko)

THERANEXUS invited to join in the HealthTech Investor Days (HTDI) 24 & 25 June in Paris

Download PDF File (363 Ko)

THERANEXUS announces the formation of its scientific Board

Download PDF File (375 Ko)

THERANEXUS to present new data on neuron-glia interactions at two scientific events

Download PDF File (380 Ko)

THERANEXUS announces issuance of Chinese patent covering its drug candidate THN102

Download PDF File (381 Ko)

THERANEXUS provides 2018 full-year results and update on activities

Download PDF File (416 Ko)

THERANEXUS announces research collaboration with IRISA using artificial intelligence technologies to enhance therapeutic targeting of neuroglial interactions

Download PDF File (376 Ko)

THERANEXUS to present new scientific data on drug candidate THN201 at AD/PD 2019, the 14th conference on Alzheimer's and Parkinson's diseases

Download PDF File (377 Ko)

THERANEXUS announces preliminary results of phase II trial of THN102 on narcolepsy patients

Download PDF File (296 Ko)

THERANEXUS reports cash position as of 31 December 2018 and provides update on current status of activities

Download PDF File (395 Ko)

THERANEXUS set to receive €6.2 million in funding from the French Investments for the
Future program, managed by Bpifrance, for the development of Neurolead,
its new lead generation platform targeting neuro-glia interactions

Download PDF File